Online citations, reference lists, and bibliographies.
← Back to Search

Functionalized Superparamagnetic Iron Oxide Nanoparticles (SPIONs) As Platform For The Targeted Multimodal Tumor Therapy

C. Janko, Teresa Ratschker, K. Nguyen, Lisa Zschiesche, R. Tietze, S. Lyer, C. Alexiou
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Standard cancer treatments involve surgery, radiotherapy, chemotherapy, and immunotherapy. In clinical practice, the respective drugs are applied orally or intravenously leading to their systemic circulation in the whole organism. For chemotherapeutics or immune modulatory agents, severe side effects such as immune depression or autoimmunity can occur. At the same time the intratumoral drug doses are often too low for effective cancer therapy. Since monotherapies frequently cannot cure cancer, due to their synergistic effects multimodal therapy concepts are applied to enhance treatment efficacy. The targeted delivery of drugs to the tumor by employment of functionalized nanoparticles might be a promising solution to overcome these challenges. For multimodal therapy concepts and individualized patient care nanoparticle platforms can be functionalized with compounds from various therapeutic classes (e.g. radiosensitizers, phototoxic drugs, chemotherapeutics, immune modulators). Superparamagnetic iron oxide nanoparticles (SPIONs) as drug transporters can add further functionalities, such as guidance or heating by external magnetic fields (Magnetic Drug Targeting or Magnetic Hyperthermia), and imaging-controlled therapy (Magnetic Resonance Imaging).
This paper references
10.1016/j.jconrel.2011.06.033
Brain tumor targeting of magnetic nanoparticles for potential drug delivery: effect of administration route and magnetic field topography.
B. Chertok (2011)
10.1080/09553008614550981
The oxygen effect in radiation inactivation of DNA and enzymes.
M. Quintiliani (1986)
10.1039/c5nr03626g
Nanoparticle distribution during systemic inflammation is size-dependent and organ-specific.
K. Chen (2015)
10.1126/science.1203486
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
R. Schreiber (2011)
10.18632/oncotarget.25135
Targeted nanoparticle delivery of therapeutic antisense microRNAs presensitizes glioblastoma cells to lower effective doses of temozolomide in vitro and in a mouse model
M. Malhotra (2018)
10.1053/j.seminoncol.2017.06.002
A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
Petros Fessas (2017)
Treating with Checkpoint Inhibitors-Figure $1 Million per Patient.
Audrey Andrews (2015)
lessons for immuno-oncology
Sengupta S. Cancer nanomedicine (2017)
10.1007/s11095-016-1958-5
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Daniel Bobo (2016)
Understanding and overcoming major barriers in cancer
S Nie (2010)
10.1016/j.jconrel.2014.05.036
State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines.
Charlene M. Dawidczyk (2014)
10.1039/C6RA02129H
Role of functionalization: strategies to explore potential nano-bio applications of magnetic nanoparticles
R. Bohara (2016)
10.4161/21624011.2014.955691
Consensus guidelines for the detection of immunogenic cell death
O. Kepp (2014)
10.3390/ijms16059368
Different Storage Conditions Influence Biocompatibility and Physicochemical Properties of Iron Oxide Nanoparticles
Jan Zaloga (2015)
10.1002/cncr.11882
Chemotherapy‐induced neutropenia
J. Crawford (2004)
10.1097/PPO.0b013e3182326004
Tumor-Specific Antigens and Immunologic Adjuvants in Cancer Immunotherapy
Teofila Seremet (2011)
10.1016/j.cytogfr.2013.01.005
Inducers of immunogenic cancer cell death.
A. Dudek (2013)
10.1016/j.addr.2010.04.009
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect.
J. Fang (2011)
10.1146/annurev-immunol-032712-100008
Immunogenic cell death in cancer therapy.
G. Kroemer (2013)
a biocompatible, size-tunable contrast agent for magnetic resonance imaging
H Unterweger (2017)
10.1016/j.ijrobp.2012.06.020
Radiation therapy to convert the tumor into an in situ vaccine.
S. Formenti (2012)
10.1016/S0959-8049(00)00350-6
Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer.
Y. Ohe (2001)
10.1097/CCO.0000000000000305
Checkpoint inhibitors: outstanding efficacy but at what cost?
J. Klastersky (2016)
10.1084/JEM.192.7.1027
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
G. Freeman (2000)
10.1007/s40259-018-0262-9
Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
M. Aapro (2018)
10.1007/s00520-015-2698-5
Chemotherapy interruptions in relation to symptom severity in advanced breast cancer
Gwen Wyatt (2015)
10.1038/s41467-017-01830-8
T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity
D. Schmid (2017)
10.2147/IJN.S138108
Non-immunogenic dextran-coated superparamagnetic iron oxide nanoparticles: a biocompatible, size-tunable contrast agent for magnetic resonance imaging
H. Unterweger (2017)
10.1021/nn800448r
Near-infrared emitting fluorophore-doped calcium phosphate nanoparticles for in vivo imaging of human breast cancer.
E. Altınoğlu (2008)
tolerance and efficacy
AS Lubbe (1996)
the phagocyte problem
HH Gustafson (2015)
10.1200/JCO.1990.8.6.963
Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis.
L. Kwak (1990)
10.1126/science.271.5256.1734
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
10.1016/j.bbrc.2012.07.108
Superparamagnetic iron oxide nanoparticles as radiosensitizer via enhanced reactive oxygen species formation.
S. Klein (2012)
10.3978/j.issn.2218-6751.2014.09.04
Nivolumab as first line monotherapy for advanced non-small cell lung cancer: could we replace first line chemotherapy with immunotherapy?
H. West (2014)
10.1016/j.nano.2016.11.010
Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models.
Cai M. Roberts (2017)
10.1016/J.NANTOD.2015.06.006
Nanoparticle Uptake: The Phagocyte Problem.
Heather Herd Gustafson (2015)
10.1097/01.rli.0000101027.57021.28
Macrophage Endocytosis of Superparamagnetic Iron Oxide Nanoparticles: Mechanisms and Comparison of Ferumoxides and Ferumoxtran-10
I. Raynal (2004)
10.1016/j.biomaterials.2011.05.004
Magnetically-enabled and MR-monitored selective brain tumor protein delivery in rats via magnetic nanocarriers.
B. Chertok (2011)
10.2147/IJN.S68539
Development of a lauric acid/albumin hybrid iron oxide nanoparticle system with improved biocompatibility
J. Zaloga (2014)
Superparamagnetic iron oxide nanoparticles as novel X-ray enhancer for lowdose radiation therapy
S Klein (2014)
10.1016/j.jconrel.2008.09.005
Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin.
Minghuang Hong (2009)
10.3390/biomedicines6030076
Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges
L. Pilla (2018)
10.1126/science.aaa4971
Neoantigens in cancer immunotherapy
T. Schumacher (2015)
10.1016/J.MATTOD.2015.08.022
Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: recent advances.
R. Revia (2016)
10.1016/j.bbrep.2017.12.002
Comprehensive cytotoxicity studies of superparamagnetic iron oxide nanoparticles
R. Patil (2018)
10.1016/j.clinthera.2016.03.026
Current Challenges in Cancer Treatment.
J. Zugazagoitia (2016)
10.1038/255197A0
Mutation selection and the natural history of cancer
J. Cairns (1975)
10.1016/J.SEMRADONC.2004.04.008
Tumor microenvironmental physiology and its implications for radiation oncology.
P. Vaupel (2004)
10.1021/acsnano.8b04315
Oral Nanoparticles Exhibit Specific High-Efficiency Intestinal Uptake and Lymphatic Transport.
K. Kim (2018)
10.3389/fimmu.2018.02266
Inert Coats of Magnetic Nanoparticles Prevent Formation of Occlusive Intravascular Co-aggregates With Neutrophil Extracellular Traps
R. Bilyy (2018)
10.2217/17435889.3.5.703
Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats.
M. Longmire (2008)
10.2147/IJN.S94139
Doxorubicin-modified magnetic nanoparticles as a drug delivery system for magnetic resonance imaging-monitoring magnet-enhancing tumor chemotherapy
Po-Chin Liang (2016)
10.1016/j.jconrel.2011.06.001
Targeted drug delivery to tumors: myths, reality and possibility.
Y. Bae (2011)
10.1021/nn5062029
Nanoparticle-based immunotherapy for cancer.
Kun Shao (2015)
10.1016/j.ctrv.2016.06.002
Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges.
F. Tartari (2016)
10 years’ experience gained
M Aapro (2018)
selection of suitable superparamagnetic iron oxide nanoparticles
M Mühlberger (2019)
challenges and future trends
Ventola CL. Cancer immunotherapy (2017)
10.1016/j.addr.2008.04.013
Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer.
M. Hamoudeh (2008)
10.1007/s10957-018-1316-3
Recent Advances
G. Chen (1939)
considerations and caveats
M Longmire (2008)
10.1021/jp5026224
Superparamagnetic iron oxide nanoparticles as novel X-ray enhancer for low-dose radiation therapy.
S. Klein (2014)
10.1053/j.seminoncol.2015.05.003
Cancer and the Immune System: Basic Concepts and Targets for Intervention.
D. Pardoll (2015)
10.4049/jimmunol.170.12.6338
Irradiation of Tumor Cells Up-Regulates Fas and Enhances CTL Lytic Activity and CTL Adoptive Immunotherapy
M. Chakraborty (2003)
10.1080/09553007714551491
Lethality in mammalian cells due to hyperthermia under oxic and hypoxic conditions.
H. Bass (1978)
10.1056/NEJM200106283442607
Side effects of adjuvant treatment of breast cancer.
C. Shapiro (2001)
10.1007/s00432-014-1767-3
Cancer active targeting by nanoparticles: a comprehensive review of literature
Remon Bazak (2014)
10.1016/J.JMMM.2016.09.034
Strategies to optimize the biocompatibility of iron oxide nanoparticles – “SPIONs safe by design”
C. Janko (2017)
10.1016/j.ijpharm.2015.05.032
Doxorubicin loaded magnetic gold nanoparticles for in vivo targeted drug delivery.
N. Elbialy (2015)
10.3402/nano.v1i0.5358
Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION)
N. Singh (2010)
10.1016/j.cell.2015.03.037
Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy
M. Goldberg (2015)
10.1039/c5nr05869d
Improving DNA double-strand repair inhibitor KU55933 therapeutic index in cancer radiotherapy using nanoparticle drug delivery.
Xi Tian (2015)
10.2147/IJN.S10881
Antibody-conjugated gold-gold sulfide nanoparticles as multifunctional agents for imaging and therapy of breast cancer
E. Day (2010)
Cancer Immunotherapy, Part 3: Challenges and Future Trends.
C. Ventola (2017)
10.2147/IJN.S156528
Dextran-coated superparamagnetic iron oxide nanoparticles for magnetic resonance imaging: evaluation of size-dependent imaging properties, storage stability and safety
H. Unterweger (2018)
10.1186/bcr3050
Detection of breast cancer cells using targeted magnetic nanoparticles and ultra-sensitive magnetic field sensors
H. Hathaway (2011)
10.3410/F.725760328.793556550
Faculty Opinions recommendation of Cancer immunotherapy: harnessing the immune system to battle cancer.
G. Vecchio (2019)
the future of biocompatible magnetism
RA Meyer (2015)
10.1021/acs.chemrev.7b00258
Nanotechnology for Multimodal Synergistic Cancer Therapy.
W. Fan (2017)
Recent insights and future challenges
F Tartari (2016)
10.1021/acsami.7b19797
pH-Responsive Magnetic Mesoporous Silica-Based Nanoplatform for Synergistic Photodynamic Therapy/Chemotherapy.
Xiang-long Tang (2018)
10.3122/jabfm.2018.04.170387
New Immunotherapies in Oncology Treatment and Their Side Effect Profiles
Pramern Sriratana (2018)
10.1016/j.ejpb.2016.01.017
Pharmaceutical formulation of HSA hybrid coated iron oxide nanoparticles for magnetic drug targeting.
J. Zaloga (2016)
10.2174/09298673113206660281
HPMA copolymer-bound doxorubicin induces immunogenic tumor cell death.
M. Šírová (2013)
10.2217/nnm.10.23
Understanding and overcoming major barriers in cancer nanomedicine.
Shuming Nie (2010)
10.1166/JNN.2015.10834
Doxorubicin-Hyaluronan Conjugated Super-Paramagnetic Iron Oxide Nanoparticles (DOX-HA-SPION) Enhanced Cytoplasmic Uptake of Doxorubicin and Modulated Apoptosis, IL-6 Release and NF-kappaB Activity in Human MDA-MB-231 Breast Cancer Cells.
D. Vyas (2015)
myths, reality and possibility
YH Bae (2011)
10.1038/nbt1340
Renal clearance of quantum dots
H. Choi (2007)
10.1016/j.ijpharm.2010.10.038
Tumor selectivity of stealth multi-functionalized superparamagnetic iron oxide nanoparticles.
Caixia Fan (2011)
Preclinical experiences with magnetic drug targeting: tolerance and efficacy.
A. Lübbe (1996)
10.1016/j.addr.2009.03.009
Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy.
P. Aggarwal (2009)
10.1007/978-1-60761-416-6_4
Mechanisms of multidrug resistance in cancer.
J. Gillet (2010)
10.1016/J.JMMM.2018.10.022
Functionalization of T lymphocytes for magnetically controlled immune therapy: Selection of suitable superparamagnetic iron oxide nanoparticles
Marina Mühlberger (2019)
Antibodyconjugated gold-gold sulfide nanoparticles as multifunctional agents for imaging and therapy of breast cancer
ES Day (2010)
a comprehensive review of literature
R Bazak (2015)
10.1016/J.BIOMATERIALS.2006.12.003
Effect of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) on human monocyte-macrophages in vitro.
K. Mueller (2007)
10.1038/s41467-017-01651-9
Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression
Jianqin Lu (2017)
10.1016/j.nano.2013.05.001
Efficient drug-delivery using magnetic nanoparticles--biodistribution and therapeutic effects in tumour bearing rabbits.
R. Tietze (2013)
10.2217/nnm.15.165
Biodegradable polymer iron oxide nanocomposites: the future of biocompatible magnetism.
R. A. Meyer (2015)
10.1186/s13075-014-0469-1
Immune checkpoint receptors in regulating immune reactivity in rheumatic disease
S. Ceeraz (2014)
10.1158/0008-5472.CAN-07-6102
Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent.
C. Patra (2008)
10.1177/1049909114549182
Advances and Challenges
V. Loerzel (2016)
10.1016/S1040-8428(01)00179-2
The cellular and molecular basis of hyperthermia.
B. Hildebrandt (2002)
10.1172/JCI83871
Cancer immunotherapy: harnessing the immune system to battle cancer.
Y. Yang (2015)
10.1016/j.jconrel.2018.07.007
Targeting of drug‐loaded nanoparticles to tumor sites increases cell death and release of danger signals
Magdalena Alev (2018)
10.2147/DDDT.S10945
Profile of ipilimumab and its role in the treatment of metastatic melanoma
S. Patel (2011)
10.3390/ijms14047341
Magnetic Drug Targeting Reduces the Chemotherapeutic Burden on Circulating Leukocytes
C. Janko (2013)
10.4155/TDE.11.72
Nanoparticle-mediated hyperthermia in cancer therapy.
D. Chatterjee (2011)
10.1016/j.trecan.2017.06.006
Cancer Nanomedicine: Lessons for Immuno-Oncology.
Shiladitya Sengupta (2017)
10.1016/j.biomaterials.2016.06.032
Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy.
Xiao Zhao (2016)
risks, consequences, and new directions for its management
J Crawford (2004)



This paper is referenced by
10.1088/1361-6528/ab91f6
Biocompatible superparamagnetic core-shell nanoparticles for potential use in hyperthermia-enabled drug release and as an enhanced contrast agent.
Yogita Patil-Sen (2020)
10.1039/c9qm00666d
Active targeting co-delivery of therapeutic Sur siRNA and an antineoplastic drug via epidermal growth factor receptor-mediated magnetic nanoparticles for synergistic programmed cell death in glioblastoma stem cells
Xueqin Wang (2020)
10.3390/pharmaceutics12100923
Mitoxantrone-Loaded Nanoparticles for Magnetically Controlled Tumor Therapy–Induction of Tumor Cell Death, Release of Danger Signals and Activation of Immune Cells
Teresa Ratschker (2020)
10.1016/j.biomaterials.2020.120229
New combination treatment from ROS-Induced sensitized radiotherapy with nanophototherapeutics to fully eradicate orthotopic breast cancer and inhibit metastasis.
Te-I Liu (2020)
10.3390/nano9111565
In Vitro and In Vivo Antioxidant Activity of the New Magnetic-Cerium Oxide Nanoconjugates
Ioana-Andreea Turin-Moleavin (2019)
10.1016/j.ijpharm.2020.119394
Superparamagnetic chitosan nanocomplexes for colorectal tumor-targeted delivery of irinotecan.
Danjun Wu (2020)
10.2147/IJN.S254745
A New Pharmacokinetic Model Describing the Biodistribution of Intravenously and Intratumorally Administered Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in a GL261 Xenograft Glioblastoma Model
Alexander P Klapproth (2020)
10.3390/pr8060706
Iron Oxide/Salicylic Acid Nanoparticles as Potential Therapy for B16F10 Melanoma Transplanted on the Chick Chorioallantoic Membrane
M. C. Predoi (2020)
10.1016/j.jinorgbio.2020.111017
Biotechnological approach to induce human fibroblast apoptosis using superparamagnetic iron oxide nanoparticles.
Fausto Ferraz (2020)
10.3390/molecules25030653
SiO2-PVA-Fe(acac)3 Hybrid Based Superparamagnetic Nanocomposites for Nanomedicine: Morpho-textural Evaluation and In Vitro Cytotoxicity Assay
A. Putz (2020)
10.3390/molecules25204721
Investigation of Dextran-Coated Superparamagnetic Nanoparticles for Targeted Vinblastine Controlled Release, Delivery, Apoptosis Induction, and Gene Expression in Pancreatic Cancer Cells
S. Albukhaty (2020)
10.7150/thno.37306
The yin and yang of imaging tumor associated macrophages with PET and MRI
S. Mukherjee (2019)
10.3390/nano10091816
Tailoring Iron Oxide Nanoparticles for Efficient Cellular Internalization and Endosomal Escape
Laura Rueda-Gensini (2020)
Semantic Scholar Logo Some data provided by SemanticScholar